QUBIS — 2022 Investments
3 investments dated 2022 · listed companies and verified rows first · show all
Aramune develops pharmaceutical and nutraceutical products targeting diseases including diabetes, obesity, cardiovascular disease, and neurodegenerative conditions.
AgTechBiotechFoodTechHealthtechMedical DevicesBelfast, GB
Brian(Professor of Molecular Nutrition)Chris Nicklin
BoardStuart
Co-investorsClarendon Fund Managers Ltd.
Vana is an open data infrastructure platform that enables individuals to control and manage the data they generate, with the ability to choose how it is used by AI systems.
AI & Machine LearningCrypto & Web3Data & Infrastructure
Art Abal(Founder)Anna Kazlauskas(Founder)
Co-investorsAbstract VenturesAlphaLab CapitalBoxGroupCaladanEarl Grey CapitalFlori Ventures+15 more
VascVersa develops a platform for vascular stem cell therapy and cell therapy manufacturing, serving the advanced therapies and clinical development sectors in vascular biology.
BiotechDeep TechHealthtechBelfast, GB
Professor Alan Stitt(Co-founder)Dr Christina O'Neill(Co-founder, CEO)Prof Reinhold Medina(Co-founder)
Co-investorsClarendon Fund Managers Ltd.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.





